Peringkat dalam Saham
#10440
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic... Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
Harga Saham
$14.66
Terakhir disinkronkan: 2026-08-28
Kapitalisasi Pasar
$839.37M
Perubahan (1 hari)
-2.67%
Perubahan (1 tahun)
557.32%
Perdagangan Climb Bio, Inc. (CLYM)
Harga CLYM dengan kapitalisasi pasar B
Kapitalisasi pasar dari Climb Bio, Inc.(CLYM)
Kapitalisasi Pasar: $839.37M
Per August 2026, Climb Bio, Inc. memiliki kapitalisasi pasar sebesar $839.37M. Ini menjadikan Climb Bio, Inc. sebagai perusahaan 10440th paling bernilai di dunia menurut data kami. Kapitalisasi pasar adalah nilai total saham beredar dari perusahaan publik dan biasanya digunakan untuk mengukur seberapa besar nilai sebuah perusahaan.
Riwayat kapitalisasi pasar Climb Bio, Inc. dari 2024 hingga 2026
CLYM dibandingkan dengan 5 teratas stocks paling populer
| Harga CLYM |
|
Aset B |
Pasar B |
Hasil |
|
|
|
|
$5.264T
|
+627,019.37%
|
|
|
|
|
$4.701T
|
+559,994.09%
|
|
|
|
|
$4.177T
|
+497,554.81%
|
|
|
|
|
$3.817T
|
+454,692.24%
|
|
|
|
|
$2.866T
|
+341,385.66%
|
